Get the Stockscreener App
5.2064
7.22%
0.3564
Corvus Pharmaceuticals Inc stock is traded at $5.2064, with a volume of 277.74K.
It is up +7.22% in the last 24 hours and up +24.70% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$4.85
Open:
$4.96
24h Volume:
277.74K
Relative Volume:
0.37
Market Cap:
$388.96M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-9.2971
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
+20.65%
1M Performance:
+24.70%
6M Performance:
+6.56%
1Y Performance:
+36.84%
1-Day Range:
$4.9165
$5.25
1-Week Range:
$4.26
$5.25
52-Week Range:
$2.54
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
5.22 | 372.57M | 0 | -27.03M | -23.97M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.19 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.08 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.54 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
649.01 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
317.85 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Comparing Corvus Pharmaceuticals Inc. in custom built stock radarsPortfolio Value Report & Expert Approved Momentum Ideas - Newser
What makes Corvus Pharmaceuticals Inc. stock price move sharply2025 Short Interest & Daily Technical Stock Forecast Reports - Newser
Corvus (CRVS) Q2 Loss Beats Estimates - AOL.com
A Tale of Resilience: Corvus Pharmaceuticals Inc Amid Stock Market Turbulence - investchronicle.com
How Resilient Is Corvus Pharmaceuticals Inc. Stock During Economic DownturnsEarnings Risk Report & High Yield Stock Recommendations - Newser
Is Corvus Pharmaceuticals Inc. stock entering bullish territoryJuly 2025 Macro Moves & Daily Growth Stock Tips - Newser
Pattern recognition hints at Corvus Pharmaceuticals Inc. upsideQuarterly Market Summary & Reliable Breakout Forecasts - Newser
Sentiment analysis tools applied to Corvus Pharmaceuticals Inc.2025 Valuation Update & Long Hold Capital Preservation Tips - Newser
Can swing trading help recover from Corvus Pharmaceuticals Inc. losses2025 Volume Leaders & Daily Risk Controlled Trade Plans - Newser
What to expect from Corvus Pharmaceuticals Inc. in the next 30 daysPortfolio Gains Report & Accurate Buy Signal Notifications - Newser
Corvus Pharmaceuticals’ Earnings Call Highlights Progress - MSN
Can volume confirm reversal in Corvus Pharmaceuticals Inc.Long Setup & Risk Controlled Daily Trade Plans - Newser
Corvus Pharmaceuticals Inc. Recovers — But Is It SustainableJuly 2025 Sentiment & Verified Momentum Stock Watchlist - 선데이타임즈
Is it time to cut losses on Corvus Pharmaceuticals Inc.July 2025 Short Interest & Capital Efficiency Focused Strategies - Newser
Can volume confirm reversal in Corvus Pharmaceuticals Inc. [Rate Cut]Long-Term Growth Plans - Newser
Corvus Pharmaceuticals and the 2025 Catalysts for Soquelitinib: A Dual-Target Biotech Play - AInvest
Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts - Seeking Alpha
Does Corvus Pharmaceuticals Inc. qualify in momentum factor screeningFree High Accuracy Alerts for ROI Traders - Newser
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q2 2025 Earnings Call Transcript - Insider Monkey
Long term hold vs stop loss in Corvus Pharmaceuticals Inc.Watchlist Summary for Active Day Traders - Newser
How Corvus Pharmaceuticals Inc. stock performs during market volatilityStrong Balance Sheet Candidates - thegnnews.com
Real time pattern detection on Corvus Pharmaceuticals Inc. stockHigh Conviction Screener with Trend Matching - Newser
How to forecast Corvus Pharmaceuticals Inc. trends using time seriesMarket Correction Proof Stock Screening Analysis - Newser
Advanced analytics toolkit walkthrough for Corvus Pharmaceuticals Inc.Smart Risk Strategy with Entry Optimization - Newser
Published on: 2025-08-11 02:13:29 - Newser
Momentum divergence signals in Corvus Pharmaceuticals Inc. chartFree Triple Digit Return Stock Predictions - Newser
Is Corvus Pharmaceuticals Inc. stock ready for a breakoutTrend Analysis for Safer Market Entries - Newser
Price action breakdown for Corvus Pharmaceuticals Inc.Free Daily Growth Stock Pick Reports - Newser
Is Now a Good Time to Reenter Corvus Pharmaceuticals Inc.Scalable Portfolio Growth Suggestions Released - beatles.ru
Corvus plans Phase II trial for soquelitinib in atopic dermatitis, targeting 200 patients with 12-week treatment window - MSN
Traders Watching For Reversal Pattern in Corvus Pharmaceuticals Inc.AI Trading Suggestions With Accuracy Focus Released - metal.it
Custom strategy builders for tracking Corvus Pharmaceuticals Inc.Free Pattern Detection for Entry Confirmation - Newser
What recovery options are there for Corvus Pharmaceuticals Inc.Real Chart Based Opportunity Identification - Newser
Transcript : Corvus Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.16%
1.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):